dinsdag,
19 september 2017
 
 
 
LAATSTE nieuws
 
 
HBA1C calculator
 
 
Oude waarde:
%
Nieuwe waarde:
mmol/mol
 
 
 
 
 
 
 
 
Exenatide en sitagliptine: verhoogd risico pancreatitis
Datum: 26.02.2013
In de onderstaande studie is onderzocht of het gebruik van de GLP-analoog exenatide en de DPP-4 remmer sitagliptine geassocieerd zijn met een verhoogd risico van een acute pancreatitis. Een totaal van 1269 patiënten met type 2 diabetes met een acute pancreatitis werden geïncludeerd in deze studie. Daartegenover werden ook 1269 controlepatiënten zonder een pancreatitis gezet. De resultaten bevestigden dat bekende risicofactoren voor een pancreatitis, zoals een verhoogd triglyceriden gehalte en alcoholgebruik, ook in deze studie risicofactoren voor een pancreatitis bleken te zijn. Tevens bleek ook het gebruik van exenatide of sitagliptine een risicofactor te zijn voor een acute pancreatitis.

Bron: JAMA Intern Med. Published online February 25, 2013.


Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus

Sonal Singh, MD, MPH; Hsien-Yen Chang, PhD; Thomas M. Richards, MS;
Jonathan P. Weiner, DrPH; Jeanne M. Clark, MD, MPH; Jodi B. Segal, MD, MPH


Importance: Acute pancreatitis has significant morbidity and mortality. Previous studies have raised the possibility that glucagonlike peptide 1 (GLP-1)–based therapies, including a GLP-1 mimetic (exenatide) and a dipeptidyl peptidase 4 inhibitor (sitagliptin phosphate), may increase the risk of acute pancreatitis.

Objective: To test whether GLP-1–based therapies such as exenatide and sitagliptin are associated with an increased risk of acute pancreatitis. We used conditional logistic regression to analyze the data.

Design: Population-based case-control study.

Setting: A large administrative database in the United States from February 1, 2005, through December 31, 2008.

Participants: Adults with type 2 diabetes mellitus aged 18 to 64 years.We identified 1269 hospitalized cases with acute pancreatitis using a validated algorithm and 1269 control subjects matched for age category, sex, enrollment pattern, and diabetes complications.

Main Outcome Measure: Hospitalization for acute pancreatitis.

Results: The mean age of included individuals was 52 years, and 57.45% were male. Cases were significantly more likely than controls to have hypertriglyceridemia (12.92% vs 8.35%), alcohol use (3.23% vs 0.24%), gallstones (9.06% vs 1.34), tobacco abuse (16.39% vs 5.52%), obesity (19.62% vs 9.77%), biliary and pancreatic cancer (2.84% vs 0%), cystic fibrosis (0.79% vs 0%), and any neoplasm (29.94% vs 18.05%). After adjusting for available confounders and metformin hydrochloride use, current use of GLP-1–based therapies within 30 days (adjusted odds ratio, 2.24 [95% CI, 1.36-3.68]) and recent use past 30 days and less than 2 years (2.01 [1.37-3.18]) were associated with significantly increased odds of acute pancreatitis relative to the odds in nonusers.

Conclusions and Relevance: In this administrative database study of US adults with type 2 diabetes mellitus, treatment with the GLP-1–based therapies sitagliptin and exenatide was associated with increased odds of hospitalization for acute pancreatitis.